Citable filing context

MCK filing events and research context

Server-rendered

MCK's research view summarizes recent SEC filing context, starting with earnings from May 7, 2026.

MCK filing events and research context
FiledItemContext
May 7, 2026earningsMcKesson reported Q4 revenues of $96.3B and adjusted EPS of $11.69, and issued FY27 adjusted EPS guidance of $43.80-$44.60.
Apr 28, 2026debt_offeringMcKesson entered a new $5.0 billion revolving credit facility, replacing existing facilities.
Apr 6, 2026debt_offeringMcKesson subsidiaries entered a $2.0 billion credit agreement, including $1.0 billion in term loans and a $1.0 billion revolving facility.
May 7, 2026Guidance: adjusted_eps43.80 to 44.60
May 7, 2026Guidance: adjusted_eps_growth13.00 to 16.00
May 7, 2026Guidance: adjusted_segment_operating_profit_growth10.00 to 13.00
May 8, 2026businessMcKesson Corporation is a diversified healthcare services leader operating through four key segments. The North American Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter drugs across the U.S. and Canada, serving pharmacies, hospitals, and manufacturers, and includes the ClarusONE sourcing joint venture. The Oncology & Multispecialty segment offers comprehensive solutions for oncology and other specialty practices, including specialty drug distribution, group purchasing organizations like Onmark, infusion services, and technology solutions via Ontada, while also supporting the U.S. Oncology Network and holding interests in PRISM Vision and SCRI. Prescription Technology Solutions addresses medication access, affordability, and adherence by connecting patients, pharmacies, providers, PBMs, and biopharma, offering services such as electronic prior authorization and price transparency, having saved patients billions. The Medical-Surgical Solutions segment supplies medical-surgical products and lab equipment to non-acute settings; however, McKesson intends to separate this segment into an independent company, with Apollo Funds acquiring a 13% minority stake for $1.25 billion. The company operates in highly competitive and regulated markets, with Cencora and Cardinal Health being primary competitors in distribution.
May 8, 2026mdaMcKesson reported robust financial performance for the fiscal year ended March 31, 2026, with revenues increasing 12% to $403.4 billion and diluted earnings per share rising 49% to $38.38. The company implemented a new four-segment reporting structure: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. North American Pharmaceutical revenue grew 11% driven by market expansion and higher volumes from retail national account customers. Oncology & Multispecialty surged 31% due to growth in provider solutions, higher specialty pharmaceutical sales, and the acquisitions of PRISM Vision ($875 million) and Core Ventures ($2.5 billion). Prescription Technology Solutions revenue increased 11% from higher demand for access solutions and technology services like electronic prior authorization. A significant strategic trend is the planned separation of the Medical-Surgical Solutions segment into an independent company, with Apollo Funds investing $1.25 billion for a 13% minority stake. Total operating expenses decreased 6%, partly due to a $480 million net gain from the sale of Norwegian operations and a $210 million LIFO credit from brand deflation. McKesson maintains a $5.7 billion accrued liability for opioid-related claims. The company returned $5.1 billion to shareholders through stock repurchases and dividends, and secured a new $5.0 billion revolving credit facility, demonstrating strong liquidity.

Source: SEC EDGAR filing text and events; period May 7, 2026; filed May 7, 2026.

Continue research

Keep researching MCK

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →